Your browser doesn't support javascript.
loading
Topical glyceryl trinitrate for the treatment of tendinopathies: a systematic review.
Challoumas, Dimitris; Kirwan, Paul D; Borysov, Dmytro; Clifford, Christopher; McLean, Michael; Millar, Neal L.
Afiliação
  • Challoumas D; Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Kirwan PD; School of Physiotherapy, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Borysov D; Physiotherapy Department, Connolly Hospital, Dublin, Ireland.
  • Clifford C; Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • McLean M; Physiotherapy Department, West Glasgow Acute Care Hospital, Glasgow, UK.
  • Millar NL; Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Br J Sports Med ; 53(4): 251-262, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30301735
OBJECTIVE: To produce a best evidence synthesis of the clinical effects of topical glyceryl trinitrate (GTN) in the treatment of tendinopathies. DESIGN: A systematic review of published randomised controlled trials (RCTs) of the use of GTN in patients with tendinopathy. DATA SOURCES: MEDLINE, Embase, Scopus and CINAHL from database inception to January 2018. METHODS: We examined RCTs comparing the effects of topical GTN with either placebo or other treatments on tendinopathy. Overall quality of each eligible study was determined based on a combined assessment of internal validity, external validity and precision. The level of evidence for each assessed parameter was rated based on the system by van Tulder et al. RESULTS: A total of 10 eligible RCTs were identified including patients with tendinopathy of the rotator cuff (n=4), wrist extensors (n=3), Achilles (n=2) and patellar (n=1) tendons. For all tendinopathies, improvements in pain were significant when comparing GTN versus placebo in the short term (<8 weeks; poor evidence). Significant improvements in midterm outcomes for treatment with GTN versus placebo included the following: patient satisfaction (strong evidence); chances of being asymptomatic with activities of daily living (strong evidence); range of movement (moderate evidence); strength (moderate evidence); pain (at night and with activity; poor evidence) and local tenderness (poor evidence). Patients treated with topical GTN reported a higher incidence of headaches than those who received placebo (moderate evidence). CONCLUSIONS AND RELEVANCE: Treatment of tendinopathies with topical GTN for up to 6 months appears to be superior to placebo and may therefore be a useful adjunct to the treating healthcare professions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor / Nitroglicerina / Tendinopatia Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor / Nitroglicerina / Tendinopatia Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article